



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
|-----------------|-------------|----------------------|---------------------|------------------|

10/525,690

10/24/2006

Raed Al-Qawasmeh

16526US01

7654

23446 7590 11/18/2009
MCANDREWS HELD & MALLOY, LTD
500 WEST MADISON STREET
SUITE 3400
CHICAGO, IL 60661

EXAMINER

POWERS, FIONA

ART UNIT

PAPER NUMBER

1626

MAIL DATE

DELIVERY MODE

11/18/2009

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

| | | | |
|------------------------------|--------------------------------------|---|--|
| Office Action Summary | Application No. 10/525,690 | Applicant(s) AL-QAWASMEH ET AL. | |
| | Examiner Fiona T. Powers | Art Unit 1626 | |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 21 September 2009.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 23 to 26, 40 to 45, 73, 74 and 78 to 153 is/are pending in the application.
- 4a) Of the above claim(s) See Continuation Sheet is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 25, 26, 42, 43, 45, 74, 79, 81, 83, 85, 87, 89, 91, 93, 95, 98 and 99 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

Continuation of Disposition of Claims: Claims withdrawn from consideration are 23, 24, 40, 41, 44, 73, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 97 and 100-153


DETAILED ACTION

Claims 23 to 26, 40 to 45, 73, 74 and 78 to 153 are pending in the application.

Receipt is acknowledged of the amendment filed September 21, 2009, which has been entered in the file.

Election/Restrictions

Applicant's election with traverse of Group XX
(phenanthrene compounds and compositions thereof) and the




species in the reply filed on September 21, 2009 is acknowledged. The traversal is on the ground(s) that claims 23 to 26, 40 to 45, 73, 74 and 78 to 153 are linked by a common inventive concept in that these claims all relate to compound having the same core structure which is indolyl imidazole moiety having aromatic rings attached to the 4- and 5-position of the imidazole ring, which groups can be attached either directly or through a fused ring system and the compounds as claimed are not anticipated nor rendered obvious by the prior art. This is not found persuasive because for unity

Art Unit: 1626

of invention to exist, the compounds must possess a special technical feature. The indolyl imidazole moiety having aromatic rings attached to the 4- and 5-position of the imidazole ring, which groups can be attached either directly or through a fused ring system is not a special technical feature because the compounds as defined in instant claims are anticipated by the prior art. Note Registry Number 330449-64-4 which is of the following structure:

RN 330449-64-4 REGISTRY
ED Entered STN: 06 Apr 2001
CN 1H-Indole, 3-[5-(4-nitrophenyl)-4-phenyl-1H-imidazol-2-yl]- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Indole, 3-[4-(4-nitrophenyl)-5-phenyl-1H-imidazol-2-yl]- (9CI)
MF C23 H16 N4 O2
SR Chemical Library
Supplier: AsInEx
LC STN Files: CHEMCATS




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

This compound anticipates at least instant claim 23. Also note Registry Number 416872-13-4 which is of the following structure:

Art Unit: 1626

RN 416872-13-4 REGISTRY
ED Entered STN: 16 May 2002
CN 1H-Phenanthro[9,10-d]imidazole, 2-(5-bromo-1H-indol-3-yl)-6,9-diiodo- (CA
INDEX NAME)
MF C23 H12 Br I2 N3
SR Chemical Library
Supplier: ChemBridge Corporation
LC STN Files: CHEMCATS



****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

This compound anticipates at least instant claims 25 and 26.

The requirement is still deemed proper and is therefore made FINAL.

Claims 23, 24, 40, 41, 44, 73, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 97 and 100-153 and claim 25 where x is other than CR11, y is other than CR12, z is other than CR13, r is other than CR14, x' is other than CR15, y' is other than CR16, z' is other than CR17 and t' is other than CR18; and claims 74 and 98 where the compound is Compound No. 82 stand withdrawn from

Art Unit: 1626

further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on September 21, 2009.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.


Claims 25 and 26 are rejected under 35 U.S.C. 102(b) as being anticipated by Registry Number 416872-13-4, entered into Registry file in STN on May 16, 2002, cited.

Registry Number 416872-13-4 whose structure is shown below is the claimed compound of the formula VI of instant claim 25 where x, y, r, x', y', and y' are CH; z and z' are C-halogen; R4 is hydrogen and R5, R7, R8 and R10 are hydrogen and R6 is

Art Unit: 1626

halogen; and the compound of the formula VII of claim 26 where R11, R12, R14, R15, R17 and R18, are hydrogen; R13 and R16 are halogen; R4 is hydrogen and R5, R7, R8 and R10 are hydrogen and R6 is halogen.

RN 416872-13-4 REGISTRY
ED Entered SIN: 16 May 2002
CN 1H-Phenanthro[9,10-d]imidazole, 2-(5-bromo-1H-indol-3-yl)-6,9-diiodo- (CA INDEX NAME)
MF C23 H12 Br I2 N3
SR Chemical Library
Supplier: ChemBridge Corporation
LC SIN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would

Art Unit: 1626

have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 25, 26, 42, 43, 45, 74, 79, 81, 83, 85, 87, 89, 91, 93, 95, 98 and 99 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 21, 22 and 24 to 27 of copending Application No. 10/579,149. Although the conflicting claims are not identical, they are not patentably distinct from each other. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instantly claimed compounds and pharmaceutical compositions are generically disclosed in the copending application.

The indiscriminate selection of "some" among "many" is *prima facie* obvious. See *In re Lemin*, 141 USPQ 814 (1964). The motivation to make the claimed compounds derives from the

Art Unit: 1626

expectation that structurally similar compounds would possess similar activity.

One of ordinary skill in the art would thus be motivated to make the claimed compounds which are embraced by the prior art in order to obtain additional beneficial products which would be useful for the same purpose. The instant claimed invention would have been suggested to one skilled in the art and therefore, the instantly claimed invention would have been rendered obvious to one skilled in the art.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Allowable Subject Matter

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Fiona T. Powers whose telephone number is 571-272-0702. The examiner can normally be reached on Monday - Friday 8:00 AM to 4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph K. McKane can be reached on 571-272-0699. The fax phone number for the

Art Unit: 1626

organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Fiona T. Powers/
Primary Examiner, Art Unit
1626

ftp
November 16, 2009